FDA approved a groundbreaking therapy for relapsed or refractory acute leukemia
Florida Cancer Specialists and Research Institute shared a post on LinkedIn:
“On November 15, 2024, the FDA approved a groundbreaking therapy for relapsed or refractory acute leukemia—marking a new era in cancer treatment.
We’re proud to share that the first-ever patient to receive this life-saving treatment was treated at our Sarasota Drug Development Unit in 2019, during a Phase 1 clinical trial.
As one of our three early-phase clinical trial sites statewide, we’ve been at the forefront of its development.
This innovative therapy, now available nationwide, has shown extraordinary results in targeting and treating this often difficult-to-treat leukemia, offering renewed hope to patients and their families.
Learn more about our participation in helping this drug become available to patients nationwide.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023